Is TBPH or TEVA more undervalued in 2026?

CirclFi compares Theravance Biopharma, Inc. (TBPH) and Teva Pharmaceutical Industries (TEVA) using 13 institutional-grade valuation models. TBPH has a Quality of Company score of 8.4/10 while TEVA scores 6.7/10.

Which is a better buy — TBPH or TEVA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do TBPH and TEVA valuations compare?

TBPH at $16.06 and TEVA at $35.32 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

TBPH vs TEVA Valuation Comparison 2026 — Intrinsic Value Analysis

TBPH

Pharmaceutical Preparations

Theravance Biopharma, Inc.

Quality

8.4

out of 10

Value Trap

SAFE

Price

$16.06

Last close

Models

10/13

Active

TEVA

Pharmaceutical Preparations

Teva Pharmaceutical Industries

Quality

6.7

out of 10

Value Trap

SAFE

Price

$35.32

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	TBPH Fair Value	TBPH Upside	TEVA Fair Value	TEVA Upside
Bayesian DCF	Intrinsic	—	—	$8.96	-74.6%
Earnings Power Value	Intrinsic	$10.88	-35.2%	$26.28	-25.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$12.24	-23.8%	$25.61	-27.5%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for TBPH vs TEVA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TBPH vs TEVA — Which Stock Is More Undervalued?

TBPH scores higher with a 8.4/10 quality rating vs TEVA's 6.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Theravance Biopharma, Inc. (TBPH) and Teva Pharmaceutical Industries (TEVA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TBPH currently trades at $16.06 with a QOC of 8.4/10, while TEVA trades at $35.32 with a QOC of 6.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).